The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program has reported that approximately 12.9% of women will get diagnosed with cancer in their lifetime. Although Black women get breast cancer at a slightly lower incidence rate (3%) than white women, Black women are 42% more likely to face mortality. This Fall, The Chrysalis Initiative (TCI) will launch BC Navi, a…
Roche has decided to withdraw its immunotherapy Tecentriq as a treatment for a type of breast cancer in the United States. The drug received accelerated approval in 2019 to treat inoperable, locally advanced or metastatic triple-negative breast cancer (mTNBC) in people whose tumors express PD-L1, a protein that may help the cancer avoid detection by the immune system. But it failed last year…
FUJIFILM, a provider of diagnostic imaging and medical informatics solutions, has announced that its ASPIRE Cristalle mammography system with digital breast tomosynthesis (DBT) now offers ScreenPoint Medical’s new, FDA cleared Transpara powered by Fusion AI for 2D and 3D mammography in the United States. ScreenPoint Medical’s AI solution, coupled with the ASPIRE Cristalle mammography system, displays breast screening findings at a doctor’s reading workstation or PACS…
Volpara Health has announced Jill Spear as the new Executive Vice President of Sales and Marketing who will drive continued growth for Volpara’s integrated software platform that assists in the delivery of personalized breast care. In this role, Spear will expand sales of the company’s breast cancer risk assessment, detection, imaging analytics and patient tracking software in North America. Earlier this year, Volpara acquired CRA Health,…
Brilliantly Warm, the app-controlled warming wearable for women who have had breast implant reconstruction after mastectomy is now available for pre-order. The device is made up of a warming pad that gets placed directly against the skin between the breast mound and undergarment. Brilliantly founder & CEO Kristen Carbone started the company in 2017 trying to solve a problem for herself. Her…
Breast cancer test maker Agendia has released new data suggesting its MammaPrint genomic diagnostic spots breast cancer patients with ultra-low risk of recurrence, who could skip chemo and are likely to keep cancer at bay for at least 20 years. This information, culled from an analysis of 70 different genes, could help oncologists tailor treatment plans for certain early-stage breast cancer cases,…
Todos Medical, a comprehensive medical diagnostics and related solutions company, today announced that it has acquired Provista Diagnostics, Inc. Provista is a medical diagnostics company based in Alpharetta, Georgia that owns the intellectual property rights to the proprietary breast cancer blood test, Videssa, and has a diagnostic testing laboratory currently performing COVID-19 PCR testing, primarily for the medical and entertainment industries. The…
2021 marks 25 years since Breast Cancer Alliance (BCA) was formed, during which time the Connecticut-based foundation has grown into a national fundraising powerhouse for breast cancer research, breast surgery fellowships and outreach and education supporting patients in underserved communities. From its inception, BCA’s mission has been to improve survival rates and quality of life for those impacted by breast cancer through…
